Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands
This article was originally published in PharmAsia News
MUMBAI - Explosive growth in India's anti-diabetes medicines market is turning arch rivals into allies. The latest example is of Eli Lilly & Co. combining forces with German giant Boehringer Ingelheim GmbH.
You may also be interested in...
Lilly says emerging markets represent “clear and significant opportunity” despite recent difficulties.
With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.
A 30% annual growth in the anti-diabetes market is fueling new launches in India, but competition is getting tougher.